Gambia: What Is Government Poicy On Prices of Drugs?

What the report says

A Foroyaa commentary published by AllAfrica on 31 August 2026 raises concerns about wide price differences for malaria medicine in The Gambia. The article says a patient with a prescription for Coatem could be charged very different amounts at different drug stores, ranging from D100 to D450, and notes that some patients appear to be experiencing different effects from different brands sold in the market.

The piece argues that the Gambia Competition and Consumer Protection Commission should work with the Ministry of Health and the Medicine Control Agency to examine both pricing and product quality. It questions why cheaper medicines would be imported if they are effective, or why ineffective medicines should remain on sale if they are not. The commentary frames drug regulation as a consumer protection issue and says affordable, effective medicine should be a basic government priority.

Foroyaa also calls for a broader review of malaria drugs available in the market, including testing to determine whether lower-cost versions provide the same cure as more expensive ones. The issue matters because medicine prices can affect access to treatment, especially for low-income patients, and because inconsistent quality could undermine public confidence in the health system. In general, drug price regulation and product testing are common public-health concerns across many countries, particularly where consumers face limited oversight or uneven access to medicines.